logo-loader

Revive Therapeutics preparing to submit paperwork for a Phase 3 FDA study of Bucillamine

Published: 15:29 16 Jun 2020 EDT

Revive Therapeutics (CSE: RVV) Chairman and CEO Michael Frank and Founder of Psilocin Pharma Corp Derrick Welsh joined Steve Darling from Proactive to discuss some recent developments for the company. Frank discusses the recent development in the repurposed drug Bucillamine and its potential use for respiratory conditions.

Welsh also told Proactive about the work Revive Therapeutics subsidiary Psilocin Corp is doing in the field of extraction and purification technology for the compound Psilocybin.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

49 minutes ago